MBX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $18,000,000.00

Insider Selling (Last 12 Months): $0.00

MBX Biosciences Insider Trading History Chart

MBX Biosciences Share Price & Price History

^$21.23

▲ +0.23 (1.10%)

As of 09/19/2024 05:29 PM ET

Days: 30 | 90 | 365

Our #1 Ticker for the Rare "Retirement Window"

From Behind the Markets | Ad

We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.

Click here for our #1 "Retirement Window" Stock >>>

MBX Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2024	Edward T Mathers	Director	Buy	500,000	$16.00	$8,000,000.00	3,614,486
9/16/2024	Life Sciences X L.P. Frazier	Major Shareholder	Buy	625,000	$16.00	$10,000,000.00	4,552,774

This diversified cannabis pioneer could make huge moves soon

From Greenlane | Ad

The cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers.

Learn more here.

SEC Filings (Institutional Ownership Changes) for MBX Biosciences (NYSE:MBX)

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Today's Range

Now: $21.23

$20.51

$21.98

50 Day Range

MA: N/A

52 Week Range

Now: $21.23

$20.51

$26.08

Volume

119,463 shs

Average Volume

130,066 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of MBX Biosciences?: MBX Biosciences' top insider shareholders include:
Life Sciences X LP Frazier (Major Shareholder)
Edward T Mathers (Director)
Learn More about top insider investors at MBX Biosciences.